ARCHIVES

Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

NS Sponsors Workshop On Prevention For Three Minority Groups

July 1, 1988

New ACS Program Honors Mary Lasker

August 31, 1984

FDA Moves to Regulate Lab-Developed Tests

August 1, 2014

Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.

April 30, 2004

FDA Proposes “Clarification” Of Clinical Studies regulations, Including Sanctions, Inspections

August 18, 1978

LAK/IL-2 Therapy Could Halt Kidney Cancer Deaths: DeVita

March 21, 1986